Clinical trial
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31]…
NCT00179621 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00179621 |
|---|---|
| Title | Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of the Efficacy and Safety of 2 Doses of Lenalidomide Versus Placebo in Red Blood Cell (RBC) Transfusion-Dependent Subjects With Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated With a Deletion (Del) 5q[31]… |
| Lead sponsor | Celgene Corporation, Industry |
| Collaborators | ICON Clinical Research Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Lenalidomide 5 mg, Lenalidomide 10 mg, Placebo |
| Enrollment | 205 |
| Start date | Jul 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2010 |
| First posted | Sep 16, 2005 |
| Last update posted | Apr 14, 2011 |
| Countries | Belgium, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: